Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity - No Study Results Posted

Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP)

This study is ongoing, but not recruiting participants.

Study NCT00622726 Information provided by The University of Texas Health Science Center, Houston

First Received: February 13, 2008 Last Updated: December 24, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	May 2015
Primary Completion Date:	November 2010 (Final data collection date for primary outcome measure)

No publications provided by The University of Texas Health Science Center, Houston

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011 Feb 17;364(7):603-15.